Centessa Pharmaceuticals plc (CNTA)
| Market Cap | 6.27B +293.4% |
| Revenue (ttm) | n/a |
| Net Income | -250.64M |
| EPS | -1.78 |
| Shares Out | 154.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,330,436 |
| Open | 40.09 |
| Previous Close | 40.18 |
| Day's Range | 40.00 - 40.56 |
| 52-Week Range | 12.39 - 40.68 |
| Beta | 1.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About CNTA
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders... [Read more]
Financial Performance
Financial StatementsNews
Global UAV Announces Proposed Acquisition of Nexus Peptide Sciences Inc.
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2026) - Global UAV Technologies Ltd. (CSE: UAV) (OTC Pink: YRLLF) (FSE: 1OZ) (the "Company") is pleased to announce that it is has entered into ...
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sl...
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical thro...
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Quarterly report: Q1 2026
Centessa Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on April 13, 2026, providing details for shareholder voting and corporate governance matters.
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that...
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under th...
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.
Why Eli Lilly Is Buying Centessa for $7.8 Billion
Bloomberg Intelligence's Sam Fazeli discusses Eli Lilly's $7.8 billion acquisition of Centessa, marking the company's entry into the sleep disorder drug market. He speaks on "Bloomberg Open Interest.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Centessa Pharmaceuticals Proxy statement: Proxy filing
Centessa Pharmaceuticals filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion
Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial $6.3 billion in a deal that expands the drugmaker's neuroscience portfolio and capabilities into sleep medici...
Centessa Pharmaceuticals Annual report: Q4 2025
Centessa Pharmaceuticals has published its Q4 2025 annual report on March 31, 2026.
Eli Lilly to buy Centessa Pharma in $6.3 billion deal
Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal worth about $6.3 billion to advance treatments for sleep-wake disorders.
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders Acquisition expands Lil...
Centessa Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
The CEO outlined a vision to lead in rare hypersomnias with a best-in-class orexin-2 agonist, supported by strong early efficacy data and a flexible, adaptive clinical strategy. Plans include expanding into broader neuroscience indications and building a commercial team.
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development mi...
Centessa Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
ORX750 has shown strong efficacy and tolerability in early studies, with registrational trials for rare hypersomnias set to begin this quarter. The platform is expanding into additional neuropsychiatric and neurodegenerative indications, supported by a robust commercial and educational strategy.
Centessa Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing orexin agonists for rare hypersomnias, with plans to start registrational studies this quarter and expand into broader neuroscience indications. ORX750 has shown best-in-class efficacy, and next-gen assets are entering the clinic to address additional CNS disorders.